«The anti-covid vaccine in pharmacies in January» Piero Di Lorenzo, President of IRBM in Pomezia (Rome): «It will cost...

[vc_row][vc_column][vc_column_text css=”.vc_custom_1595928590974{margin-bottom: 30px !important;}”]Libero Quotidiano

«If all goes as planned, large-scale production could start in late September. […] Given the pandemic, I am quite sure the regulatory agencies will reduce the approval time». IRBM, the Italian research institute for medical science and organic chemistry, has contributed to the development of vaccine. During the interview, Di Lorenzo says that the first doses could be available on the market early next year, thanks to AstraZeneca’s huge production capacity. He also talks about the role played by Italy in the vaccine distribution and the good work done by the Italian Minister Speranza.

Article published on Libero Quotidiano – 27/07/2020

Download pdf[/vc_column_text][/vc_column][/vc_row]

Comments (0)

Read more

Interview with Piero Di Lorenzo. The Italian company. Enthusiasm in Rome: «But now we have to be cautious»

[vc_row][vc_column][vc_column_text css=”.vc_custom_1596210922149{margin-bottom: 30px !important;}”]Corriere della Sera

Interview with Piero Di Lorenzo The Italian company Enthusiasm in Rome: «But now we have to be cautious»

photo source: Corriere della Sera

IRBM’s researchers and laboratory technicians are enthusiastic about the results published in The Lancet. They have been working restlessly for months to develop the vaccine. Oxford developed the viral inoculum, while IRBM took advantage of its expertise in the field of adenovirus. Piero Di Lorenzo, President and CEO of IRBM, is cautious but optimistic. «We are proud to be part of this team together with AstraZeneca and the Italian Government», he admits.

Article by Margherita De Bac published on Corriere della Sera – 21/07/2020

Download pdf[/vc_column_text][/vc_column][/vc_row]

Comments (0)

Read more

The Italian partners: «Vaccine will be ready in September. We will have the doses soon

[vc_row][vc_column][vc_column_text css=”.vc_custom_1595836373508{margin-bottom: 30px !important;}”]la Repubblica

Interview with Matteo Liguori: «Everything will depend on tests on subjects at risk»
The Italian partners: «Vaccine will be ready in September. We will have the doses soon »

«The Lancet report is the first truly relevant result published on this vaccine candidate», explains Matteo Liguori, Managing Director of IRBM in Pomezia (Rome). The Italian company has produced the first doses for clinical trial, in collaboration with the University of Oxford. «The vaccine is safe and stimulates production of antibodies in 90% of cases». Liguori also points out that the result of tests on subjects at risk will be crucial. «We hope the vaccine will be distributed by December […] The Italian government has signed an agreement with AstraZeneca, together with other countries, for a first tranche of 60 million doses. The doses will be distributed according to algorithms that are part of the agreement itself».

Article published on la Repubblica21/07/2020

Download pdf[/vc_column_text][/vc_column][/vc_row]

Comments (0)

Read more

Covid, Minister Speranza to the Washington Post: “The Oxford-Pomezia vaccine will arrive before the others”

[vc_row][vc_column][vc_column_text css=”.vc_custom_1593099082599{margin-bottom: 30px !important;}”]Il Messaggero

“This vaccine will arrive before the others, according to scientists. No other company can claim that we will have the vaccine by the end of this year. I’ve got goose bumps thinking about the chance of saving lives”, declared Health Minister Roberto Speranza during his visit to IRBM in Pomezia (Rome). The Italian company is collaborating on the clinical trials with the University of Oxford.

Article published on ilmessaggero.it – 23/06/2020

Read the original article on ilmessaggero.it[/vc_column_text][/vc_column][/vc_row]

Comments (0)

Read more

Visit to IRBM. Minister Speranza: “Italy, a key role to have the vaccine”

[vc_row][vc_column][vc_column_text css=”.vc_custom_1592901027215{margin-bottom: 30px !important;}”]Il Giornale logo

Health Minister Roberto Speranza visited the Italian IRBM yesterday. The company is collaborating on the clinical trials with the University of Oxford. “Only a safe, effective vaccine can take us out of the emergency – says Speranza – for this reason Italy’s role is relevant in the European deal signed recently. We are proud of our scientists and of the excellence of Italian research.”

Article published on il Giornale19/06/2020

Download pdf[/vc_column_text][/vc_column][/vc_row]

Comments (0)

Read more

Speranza visits the Italian company that is working on the vaccine

[vc_row][vc_column][vc_column_text css=”.vc_custom_1592897817227{margin-bottom: 30px !important;}”]Il Foglio

“We are proud of our scientists and of the excellence of Italian research”, says the Minister. “Thanks to the European agreement, Italy will guarantee a vaccine to the people”, says Di Lorenzo (CEO of IRBM)

This morning the Health Minister Roberto Speranza, together with Andrea Magrini, the director general of Italian medicines agency AIFA, visited IRBM in Pomezia (Rome) and its researchers. Through its subsidiary Advent, the Italian company is collaborating on clinical trials with the Jenner Institute of Oxford University. “We are grateful to the Minister and to Prof. Magrini for their visit”, said Piero Di Lorenzo, President and CEO of IRBM. “Only a safe, effective vaccine can take us out of the emergency”, wrote Speranza on Facebook after visiting the laboratories in Pomezia. “We are proud of our scientists and of the excellence of Italian research”.

Article published on ilfoglio.it – 18/06/2020

Read the original article on ilfoglio.it[/vc_column_text][/vc_column][/vc_row]

Comments (0)

Read more

Coronavirus. Pomezia vaccine, first trial results in 10 days. The USA and China are also competing

[vc_row][vc_column][vc_column_text css=”.vc_custom_1592408021124{margin-bottom: 30px !important;}”]Il Messaggero

Italy, Germany, France and the Netherlands have formed an alliance to secure the vaccine for Europe. After running the risk of being left on the sidelines, the Italian government has signed a contract with AstraZeneca for 400 million doses. The vaccine, developed by the Oxford University in collaboration with the Italian company IRBM (located in Pomezia, Rome) through its vaccines division Advent, has been chosen as vaccine candidate. Results of phase I trials will be disclosed in 10 days.

Article published on ilmessaggero.it – 15/06/2020

Read the original article on ilmessaggero.it[/vc_column_text][/vc_column][/vc_row]

Comments (0)

Read more

The company from Pomezia (Rome) is a forerunner for vaccines: “Production has started, we will be ready in September”

[vc_row][vc_column][vc_column_text css=”.vc_custom_1592570494687{margin-bottom: 30px !important;}”]La Stampa

Interview with Piero Di Lorenzo, the entrepreneur at the head of IRBM, the Italian company that collaborates with the Oxford University. “We have shown that betting on scientific research is possible in Italy”. Piero Di Lorenzo bought IRBM from the multinational Merck eleven years ago, but he would never have thought that now, with the same money, he would not even buy the gate of his company. “The bet is won”. Di Lorenzo talks about his collaboration with Oxford and explains how the vaccine has been developed and how close it really is.

Article by Paolo Russo published on lastampa.it – 14/06/2020

Read the original article on lastampa.it[/vc_column_text][/vc_column][/vc_row]

Comments (0)

Read more

Italy in pole position in the vaccine race

[vc_row][vc_column][vc_column_text css=”.vc_custom_1592398278162{margin-bottom: 30px !important;}”]Il Tempo logo

The race for a coronavirus vaccine began months ago in the world, and “Europe is far ahead of the USA”. The vaccine developed in Oxford in partnership with the Italian company IRBM of Pomezia (Rome) is in pole position. “We are making sure that a significant part of the production takes place in Italy, and that Italy is one of the leading countries”, says Walter Ricciardi, Adviser to the Minister of Health and member of the WHO’s Executive Board. “Vaccine is the real solution”, he points out.

Article published on il Tempo11/06/2020

Download pdf[/vc_column_text][/vc_column][/vc_row]

Comments (0)

Read more

Flu vaccine for children and elderly, hypothesis under consideration

[vc_row][vc_column][vc_column_text css=”.vc_custom_1590420061891{margin-bottom: 30px !important;}”]ansa.it

Flu vaccination could be recommended to all children and the elderly by the Ministry of Health. Meanwhile, the University of Oxford is testing the coronavirus vaccine developed with the Italian IRBM, based in Pomezia (Rome). The next phase of clinical trial will involve more than 10.200 people of different age groups and will monitor the effects on the immune system: good results have already been achieved through tests on monkeys.

Article published on ansa.it – 22/05/2020

Read the original article on ansa.it[/vc_column_text][/vc_column][/vc_row]

Comments (0)

Read more